BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced that new blinded data on approximately 45 patients from its Phase 2 clinical trial evaluating hypoxic-cultured mesenchymal stem cells for the treatment of chronic lumbar disc disease will be presented at the 2026 Orthopaedic Research Society Annual Meeting. The meeting will be held March 27-31, 2026, at the Charlotte Convention Center in Charlotte, North Carolina.

Francisco Silva, BioRestorative's Vice President of Research and Development, will present its poster, titled, "Late-Stage Phase 2 Clinical Safety and Efficacy Data on Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells: Study Update," on March 28, 2026. The Company will issue a press release pre-market that day, detailing the newly reported data. Chronic lumbar disc disease is a leading cause of chronic lower back pain and disability, affecting millions of patients globally and representing a significant unmet need for non-surgical regenerative therapies.